Across TCGA pan-cancer cohorts, THSD4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated THSD4 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher THSD4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated THSD4 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where THSD4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.863	0.661	.001	34	view →
CCRCC	DFS	Median	III,IV	0.145	0.774	.016	30	view →
LUAD	DFS	Median	II,III,IV	0.675	0.981	.019	9	view →
LSCC	OS	Median	II,III,IV	0.898	1.000	.013	5	view →
UCEC	OS	Median	All	0.851	0.981	.011	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: THSD4 tumor-vs-normal RNA expression · all THSD4 data types